Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis
Heather Raglin, Editor
![Alphyn Logo 1 Alphyn Logo 1](https://v769c6.p3cdn1.secureserver.net/wp-content/uploads/2021/04/Alphyn-Logo-1-200x200.png)
Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195